Exact Sciences: 3Q Earnings Snapshot
MADISON, Wis. (AP) _ Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $45.4 million in its third quarter.
The Madison, Wisconsin-based company said it had a loss of 37 cents per share. Losses, adjusted for non-recurring costs, were 30 cents per share.
The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 42 cents per share.
Target and Lowe’s jump while Harford Financial falls
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday:
Target Corp., up $2.67 to $85.94
The retailer raised its annual forecasts as its sales over the internet and in stores both climbed.
Lowe's Cos., up $5.78 to $105.52
The home improvement retailer had a solid second quarter as Americans continue to invest in their homes.
Super Micro Computer Inc., down $2.70 to $15.65
The server technology company said the Nasdaq will move to delist its stock.
Exact Sciences: 2Q Earnings Snapshot
MADISON, Wis. (AP) _ Exact Sciences Corp. (EXAS) on Wednesday reported a loss of $36.4 million in its second quarter.
On a per-share basis, the Madison, Wisconsin-based company said it had a loss of 30 cents.
The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 33 cents per share.
Exact Sciences seeks $2.6 million in TIF for next phase of expansion
Booming Exact Sciences Corp. is seeking the remaining $2.6 million of capacity in a tax incremental financing (TIF) district to help pay for a parking garage at the $88.2 million second phase of its new campus along the Beltline on Madison’s West Side.
Exact Sciences hires Mayo Clinic Dr. Paul Limburg as co-chief medical officer
Mayo Clinic gastroenterologist and professor of medicine Dr. Paul Limburg has joined Exact Sciences Corp. as co-chief medical officer.
Exact Sciences Corp. has topped the 1 million mark -- more than 1 million patients have been screened for colorectal cancer using the Madison company's Cologuard home test kit.
Two local biotechs are raising a lot of money.
Exact Sciences is No. 1 gainer among Wisconsin stocks in 2017
As the stock market climbed to record heights for a second straight year, more Wisconsin stocks went up than down in 2017.
But no percentage increase was anywhere near as big as that of Exact Sciences Corp.
Exact Sciences shares dip after preliminary fourth-quarter report
Exact Sciences Corp.'s stock took a hit in trading on Monday even though the Madison maker of Cologuard reported preliminary results for the fourth quarter and the full 2017 fiscal year showing sharp increases in the use of its colorectal cancer DNA stool test.
Exact Sciences execs sell more than $30 million worth of stock
Three top executives of Exact Sciences Corp. have sold $31.4 million worth of company stock over a three-month period, from Sept. 5 through Dec. 1.
CEO and chairman Kevin Conroy accounts for more than half of that — $16.1 million.
Exact Sciences Corp. stock jumped as much as 5 percent during the day's trading on Wednesday, after the Madison cancer test company announced it will build its second Cologuard processing lab on the Southwest Side at the former Spectrum Brands headquarters.
Exact Sciences Corp. is making it official: The Madison cancer test company will announce today that it has bought the former Spectrum Brands property on the city’s Southwest Side and will expand there.
Madison officials to continue discussing public funds for Exact Sciences expansion
The conversation continues on whether Madison will provide public funds to aid the expansion plans of Exact Sciences Corp.
Exact Sciences takes over former Spectrum Brands HQ — temporarily, at least
Exact Sciences Corp. is preparing to move into the former Spectrum Brands headquarters, starting this fall, with more than 400 employees expected to be housed there by the end of 2017.
Exact Sciences says its next cancer test could begin studies in 2018
Exact Sciences Corp. gave a rosy report Tuesday on its finances for the second quarter of 2017, and said a major study on its second product in the pipeline — a test for lung cancer — will likely begin in early 2018.
MADISON, Wis. (AP) — A Wisconsin company is seeing success after facing issues over an attempted move into new office space.
Sales of Exact Sciences Corp.'s Cologuard DNA stool test for colorectal cancer are on the rise and its stock is hitting record highs, the Wisconsin State Journal (http://bit.ly/2tIUIjC) reported.
For what’s believed to be the first time in nearly four years, there is a solid contender that could turn the former Spectrum Brands property into a major employment site again.
- Wisconsin State JournalExact Sciences takes aim at 15 types of cancer, envisions universal testJanuary 27, 2019
- Wisconsin State JournalMadison looks to expand, strengthen development tool aimed at adding jobsJanuary 14, 2019
- Wisconsin State JournalExact Sciences launches studies to expand its attack on cancerDecember 23, 2018
- Wisconsin State JournalExact Sciences signs deal with Epic Systems, hikes sales, widens lossesNovember 4, 2018
- Wisconsin State JournalExact Sciences' stock soars on news that Pfizer will market Cologuard testAugust 22, 2018
Exact Sciences Corp. ’s fortunes are on the upswing.
Sales of its Cologuard test for colorectal cancer are on the rise, its stock is hitting record highs, and the company has padded its coffers with the sale of even more stock.
One week after hitting an all-time high, Exact Sciences Corp. stock slipped as much as 8 percent in early trading Monday after a well-known stock blogger issued a negative report about the Madison company and then blasted CEO Kevin Conroy in a heated exchange on CNBC.
Exact Sciences Corp., Judith and Nick Topitzes, Sandy and Jun Lee and two anonymous couples have pledged $100,000 each as matching gifts for a 2017 fundraising campaign announced Monday by the Overture Center for the Arts.
Exact Sciences and Mayo Clinic offer hope for a lung cancer blood test
Exact Sciences Corp. and Mayo Clinic are touting early results of a study on a blood test for lung cancer.
Exact Sciences reports fourth-quarter loss but beats Wall Street predictions
Exact Sciences Corp. stock hit its highest point in a year during heavy trading on Tuesday after the Madison cancer-screening device company reported a loss for the last three months of 2016 that was smaller than analysts expected while the company’s revenue more than doubled.
Exact Sciences Corp. is making more stock available to the public to raise money for marketing Cologuard, the Madison company's test for colorectal cancer.
Exact Sciences’ stock soars on task force’s final recommendations for Cologuard tests
- Globe NewswireMarket Trends Toward New Normal in Eaton Corporation, Kite Realty Group Trust, Intercontinental Exchange, SS&C Technologies, Exact Sciences, and Oshkosh — Emerging Consolidated Expectations, Analyst RatingsMarch 4, 2019
- Globe NewswireAnalysis: Positioning to Benefit within Rollins, Hospitality Properties Trust, Exact Sciences, Tenet Healthcare, Entergy, and Calithera Biosciences — Research Highlights Growth, Revenue, and Consolidated ResultsJanuary 28, 2019
- Globe NewswireReport: Exploring Fundamental Drivers Behind MRC Global, Exact Sciences, Owens-Illinois, Copart, Cognizant Technology Solutions, and Owens & Minor — New Horizons, Emerging Trends, and Upcoming DevelopmentsNovember 5, 2018
- Globe NewswireDetailed Research: Economic Perspectives on Ashland Global, Pattern Energy Group, Jacobs Engineering Group, Olin, Exact Sciences, and Comcast — What Drives Growth in Today's Competitive LandscapeOctober 4, 2018
- Globe NewswireResearch Report Identifies PDL BioPharma, TEGNA, Patterson Companies, Boardwalk Pipeline Partners, Exact Sciences, and Berkshire Hathaway with Renewed Outlook — Fundamental Analysis, Calculating Forward MovementJune 26, 2018